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Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.11.044Objective: Early cell death remains a major limitation of skeletal myoblast trans-
plantation. Because the poor vascularization of the target scars contributes to cell
loss, we assessed the effects of combining skeletal myoblast transplantation with
administration of hypoxia-inducible factor 1, a master gene that controls the
expression of a wide array of angiogenic factors.
Methods: A myocardial infarction was created in 56 rats by means of coronary
artery ligation. Eight days later, rats were randomly allocated to receive in-scar
injections of culture medium (control animals, n 11), skeletal myoblasts (5 106,
n  13), adenovirus-encoded hypoxia-inducible factor 1 (1.0  1010 pfu/mL, n 
7), or skeletal myoblasts (5  106) in combination with an empty vector (n  3) or
active hypoxia-inducible factor 1 (1.0  1010 pfu/mL, n  13). A fifth group
(n  9) underwent a staged approach in which hypoxia-inducible factor 1 (1.0 
1010 pfu/mL) was injected at the time of infarction, followed 8 days later by skeletal
myoblasts (5  106). Left ventricular function was assessed echocardiographically
before transplantation and 1 month thereafter. Explanted hearts were then processed
for the immunohistochemical detection of myotubes, quantification of angiogenesis,
myoblast engraftment, and cell survival.
Results: Baseline ejection fractions were not significantly different among groups
(35%-40%). One month later, ejection fraction had decreased from baseline in
control hearts and in those injected with hypoxia-inducible factor 1. In contrast, it
did not deteriorate after injections of skeletal myoblasts alone or combined with
either the empty vector or active hypoxia-inducible factor 1 administered sequen-
tially. The most striking change occurred in the skeletal myoblast plus hypoxia-
inducible factor 1 combined group in which ejection fraction increased dramati-
cally (by 27%) above baseline levels and was thus markedly higher than in all other
groups (P  .0001 and P  .001 vs control animals and animals receiving
hypoxia-inducible factor 1, respectively). Compared with skeletal myoblasts
alone, the coadministration of hypoxia-inducible factor 1 resulted in a significantly
greater degree of angiogenesis, cell engraftment, and cell survival.
Conclusion: Induction of angiogenesis is an effective means of potentiating the
functional benefits of myoblast transplantation, and hypoxia-inducible factor 1 can
successfully achieve this goal.
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TXOver the past years, cell transplantation has emergedas a potential new therapeutic option in patientswith heart failure.1 This approach is based on a
substantial number of experimental studies that have dem-
onstrated that implantation of different cell types (primarily
skeletal myoblasts,2-5 bone marrow– derived mesenchymal
cells,6 and embryonic stem cells7) into scar tissue could
rejuvenate these areas through favorable changes in extra-
cellular matrix remodeling,8 direct contribution to contrac-
tile activity,9 and/or paracrinally mediated recruitment of a
resident pool of cardiac stem cells.10,11 These data have
paved the way for early clinical surgical12 or catheter-
based13 trials, the functional results of which, although
encouraging, need to be further validated by randomized
trials, some of which are already underway.
However, a major limiting factor of the procedure is the
massive rate of graft death occurring shortly after the injec-
tions,14 largely because of the ischemic nature of the envi-
ronment in which the cells are implanted. This assumption
has thus led to the concept that, correlatively, cell survival
and the expectedly related functional improvement might be
increased by enhancing the vascular supply of the grafted
area. The present study was therefore designed to test this
hypothesis by assessing, in a rat model of myocardial in-
farction, the effects of combining skeletal myoblast trans-
plantation with hypoxia-inducible factor 1 (HIF-1), a
master gene that controls the expression of several genes
encoding angiogenic growth factors.15,16
Methods
The experiments complied with the “Principles of Laboratory
Animal Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal Re-
sources, Commission on Life Science, National Research Council,
and published by the National Academy Press, revised 1996.
Cell Cultures
Primary muscle cell cultures were prepared from newborn Wistar
male rats (Charles Rivers, Arbresle, France) by using a previously
established protocol.2 The day of transplantation, cells were
thawed and washed 3 times in modified Eagle’s medium with 0.5%
bovine serum albumin (fraction V; Sigma, St Louis, Mo). Samples
of 5  106 cells were prepared and kept at room temperature until
transplantation. Viability and the percentage of skeletal myoblasts
were assessed by means of trypan blue exclusion and desmin
immunolabeling, respectively.
HIF-1
The HIF-1/VP-16 hybrid was constructed by truncating HIF-1
at amino acid 390 and then joining the transactivation domain of
herpes simplex virus VP-16 downstream. Gene expression is con-
trolled by the cytomegalovirus immediate early enhancer-
promoter. The efficacy of this HIF-1/VP-16 construct has been
demonstrated both in vitro and in animal experiments.17,18 In the
174 The Journal of Thoracic and Cardiovascular Surgery ● Julypresent study the construct was inserted into the genome of an
adenoviral 2 vector (Genzyme BioSurgery, Cambridge, Mass), as
described previously.19,20 The empty vector was constructed in a
fashion similar to that of Ad2/HIF-1/VP16, except that it lacked
a transgene; as such, it has been shown to only induce a mild and
transient inflammatory response that does not generate noticeable
angiogenic effects.
Myocardial Infarction Model
Female Wistar rats (Charles Rivers) were anesthetized with isoflu-
rane (1%-3%) with a constant flow of oxygen (1-2 L/min) and
ventilated with an endotracheal tube. A myocardial infarction was
then created through ligation of the left coronary artery with a 6-0
polypropylene snare (Ethicon Inc, Somerville, NJ) through a left
lateral thoracotomy.
Experimental Protocol
Eight days after creation of infarction, the chest was reopened
through a median sternotomy. Simultaneously, the cells were
thawed and pelleted. Rats were then randomly allocated to receive
intramyocardial injections of culture medium alone (control ani-
mals, n  11), skeletal myoblasts alone (5  106, n  13),
adenovirus-encoded HIF-1 alone (1.0  1010 pfu/mL, n7), or
skeletal myoblasts (5  106) in combination with either the empty
vector for HIF-1 (n  3) or active HIF-1 (1.0  1010 pfu/mL,
n  13) after mixing of the 2 solutions in the same syringe. A fifth
group (n 9) underwent a staged approach, in that HIF-1 (1.0
1010 pfu/mL) was injected at the time of infarction, whereas
skeletal myoblasts (5  106) were delivered in a usual manner 8
days later.
All injections consisted of a 150-L volume, which was deliv-
ered in 4 or 5 sites in the core and at the borders of the scar by
using a 29-gauge needle.
Immunosuppression with cyclosporine (INN: ciclosporin; 10
mg/kg; Novartis Pharma, Rueil-Malmaison, France) was started at
the time of myocardial infarction and continued thereafter until
death.
End Points
Left ventricular function. Left ventricular (LV) function was
assessed by means of 2-dimensional echocardiography shortly
before injections (ie, 6 and 8 days after infarction) and 1 month
thereafter according to a previously described protocol.2 After
endocardial tracings with the leading-edge method, measurements
of maximal LV long-axis lengths and areas were performed on
cine loops at end diastole (at the time of apparent maximal cavity
dimension) and end systole (at the time of maximum anterior
motion of the posterior wall). These data were then used to
calculate LV end-diastolic volume (LVEDV) and LV end-systolic
volume (LVESV) and ejection fraction (EF; EF %  100
LVEDV  LVESV⁄LVEDV) by using the single-plane area-length
method V  8A2⁄3L. All measurements were made by a single
experienced observer who was blinded to the treatment group.
Measurements were averaged over 3 to 5 consecutive cardiac
cycles.
Cell engraftment and angiogenesis. After the last echocardio-
graphic assessment, the animals were killed. Because the primary
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TXtection expected from HIF-1 was related to increased angiogen-
esis, only hearts injected with either myoblasts alone or myoblasts
in combination with HIF-1 were used for this part of the protocol.
Hearts of these 2 groups were harvested and separated in 2 halves
by a short-axis section through the midportion of the infarcted
area. Histologic and immunohistochemical studies were carried
out from the 2 blocks of each heart on 5-m-thick cryostat sections
fixed in acetone for 10 minutes. For histologic assessment (ie,
extent of scarring and myoblast engraftment), the sections were
stained with toluidine blue. For immunohistochemistry, a standard
3-step alkaline phosphatase (red labeling) technique, peroxidase
(brown labeling) technique, or both was used to detect skeletal
myogenic cells (red labeling) with a monoclonal antibody against
the skeletal muscle fast myosin heavy chain isoform (clone My32,
Sigma) or rat endothelial cells (brown labeling) with the anti-rat
endothelial cell monoclonal antibody (RECA; Serotec, Oxford,
United Kingdom), or both with combined immunohistochemistry
on the same tissue section.
For each rat, the heart section containing the best engraftment
of skeletal myocytes was selected for quantification of angiogen-
esis. To this end, the number of RECA-labeled capillary sections
was counted in an average of 10 randomly selected microscopic
fields by using a light microscope with a grid-eye piece at a
magnification of 10 and expressed as a number per unit of area
(625 m2). The percentage of engraftment was calculated as the
ratio of the myosin-positive area to the infarcted area, as measured
with computerized planimetry.
Cell survival. In a subset of experiments involving transplan-
tation of male myoblasts into female recipients, left ventricles
removed at the end of the study were snap-frozen in liquid nitrogen
and stored at 80°C. Muscles were thawed on ice, minced, and
digested to homogeneity overnight at 4°C in lysis buffer (Roche,
Basel, Switzerland). DNA was then isolated from whole homog-
enates by using the Wizard DNA purification kit (Promega, Char-
bonnieres, France) and dissolved in Tris-HCl buffer (5 mmol/L,
pH 8.5).
To determine the amount of male cells, we used SYBERGreen
(Applied Biosystems, Foster City, Calif) double-stranded, DNA-
binding, dye chemistry-based, real-time, quantitative polymerase
chain reaction (PCR). A rat Y chromosome–specific sequence in
the sex-determining region y (sry) gene was used to determine the
relative quantities of male cells after transplantation. Primers used,
5=-CAGACTCATCGAAGGG-3= (forward) and 5=-AGTCCTC-
CAAGAACCAG-3= (reverse), were designed with the Primer Ex-
press software (Applied Biosystems). Known quantities (1.5 
107 to 1.5 1010 g/L) of a pGEM-T easy vector containing the
161-bp fragment specific for the sry gene (pGEM-Teasy-SRY161),
generated by means of PCR amplification with the above-
described Y chromosome-specific primers, were used as internal
standards for amplification efficiency and specificity. The absolute
number of surviving cells compared with those initially trans-
planted was extrapolated from the standard curve established with
dilutions of genomic DNA extracted from known numbers of male
rat cells (2.5  106 to 10  106) injected in a separate set of
infarcted female hearts. There was an excellent correlation be-
tween the number of injected cells and the amount of sry PCR
products, and as for 2.5, 5, 7.5, and 10  106 cells, the amount of
fluorescence (measured in triplicate for each batch of cells) aver-
The Journal of Thoraciaged 2.62  102, 6.16  102, 9.83  102, and 14.2  102,
respectively (goodness of fit, 0.84).
Data Analysis
All functional and histologic studies were performed in a blinded
fashion. Because of the inappropriateness of assuming a Gaussian
distribution of values given the small sample sizes, nonparametric
tests were used for comparing between-group and within-group
differences (Mann-Whitney and Wilcoxon tests, respectively). For
that same reason, results are expressed as median (minimal-
maximal) values. The critical  level was set at .05, and the Holm
method was used to adjust for multiple comparisons.
Results
Characterization of Injectates
At the time of transplantation, the percentage of myogenic
cells, as assessed by using a positive staining for desmin,
was 38.6%. The postthawing viability rate, as assessed by
means of exclusion of trypan blue, was 91%.
Functional Outcomes
Baseline echocardiographically determined EFs, expressed
as median values, ranged from 30.6% to 41.6% but were not
significantly different among groups, as assessed by means
of nonparametric testing. However, 1 month after transplan-
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Figure 1. Posttransplantation EFs. Contrls, Control animals;
myobl, myoblasts. The staged group refers to the injection of
HIF-1 at the time of infarction, followed 8 days later by myoblast
transplantation; the combi group refers to the concomitant ad-
ministration of HIF-1 and myoblasts 8 days after myocardial
infarction. *P  .0001 versus control animals, P  .001 versus
HIF-1 (after adjustment for multiple comparison analysis). †P 
.03 versus myoblasts (not statistically significant after adjustment
for multiple comparisons). ‡P  .006 versus control animals, P 
.03 versus HIF-1 (not statistically significant after adjustment for
multiple comparisons).can be summarized as follows: EF decreased from baseline
c and Cardiovascular Surgery ● Volume 130, Number 1 175
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TXin control hearts (from 38.7% [31.6%-44.9%] to 29.1%
[8.5%-46.8%]; relative decrease, 20.7%) and in hearts
injected with HIF-1 (from 40.4% [27.9%-43.9%] to 34.4%
[13.3%-46.1%]; relative decrease,14.9%). In contrast, EF
did not deteriorate over time after injections of skeletal
myoblasts, irrespective of whether they were given alone
(before, 30.6% [24.8%-40.7%]; after, 34.9% [24.7%-
57.3%]; relative increase, 5.6%) or in combination with
either active HIF-1 given sequentially (before, 35.2%
  M y o b l a s t
x  4
Figure 2. Representative picture of a myoblast-trans
myoblasts and HIF-1 (right panel). At higher magnifi
staining) and fast skeletal myosin–positive cell engraf




Control animals (n  11) 0.40 (0.32-0.49)
Myoblasts (n  13) 0.43 (0.26-0.53)
Myoblasts  empty vector (n  3) 0.44 (0.36-0.47)
HIF-1 (n  7) 0.37 (0.30-0.44)
Myoblasts  HIF-1 (staged, n  9) 0.38 (0.28-0.58)
Myoblasts  HIF-1 (combined, n  13) 0.41 (0.28-0.51)
Data are expressed as median (minimal-maximal) values. In the staged gro
before myoblast transplantation); in the combined group both hypoxia-in
myocardial infarction. EDV, End-diastolic volume; ESV, end-systolic volumcombined therapy.
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crease, 2.2%) or the empty adenoviral vector (before, 41.6%
[24.6%-45.2%]; after, 41.5% [25.1%-42.1%]), although the
small size of this latter sample limits the meaningfulness of
the conclusions. The most striking change occurred in the
group receiving concomitant delivery of myoblasts and
HIF-1 because EF increased dramatically above baseline
levels (before, 34.9% [25.0%-44.3%]; after, 44.8% [22.9%-
56.2%]; relative increase, 27.6%), so that at the 1-month
       M y o b l a s t  + H I F - 1 α
x   4
ed heart (left panel) and a heart treated with both
n (20), the greater degree of angiogenesis (brown
t (red staining) is clearly visible in the heart receiving
L) ESV (mL)
After Tx Baseline After Tx
0.55 (0.41-1.08) 0.25 (0.20-0.32) 0.40 (0.22-0.86)
0.53 (0.34-0.99) 0.30 (0.15-0.39) 0.37 (0.14-0.73)
0.64 (0.41-0.64) 0.24 (0.21-0.35) 0.37 (0.24-0.47)
0.50 (0.36-0.75) 0.22 (0.17-0.30) 0.30 (0.24-0.65)
0.63 (0.34-0.82) 0.27 (0.16-0.41) 0.38 (0.21-0.59)
0.50 (0.38-1.08) 0.24 (0.19-0.38) 0.28 (0.18-0.83)
poxia-inducible factor 1 was injected at the time of infarction (ie, 8 days
le factor 1 and myoblasts were injected simultaneously 8 days after
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TXstudy point, it was markedly higher than in all other groups,
the difference being significant versus control animals and
HIF-1–injected hearts (P  .0001 and P  .001, respec-
tively). This improvement was primarily related to smaller
changes in LV end-systolic volumes (Table 1), which only
increased by 7.7% above baseline in hearts receiving myo-
blasts and HIF-1, a figure 10-fold, 7-fold, and 4-fold lower
than those yielded by control animals, HIF-1–treated
hearts, and myoblast-grafted hearts, respectively. Con-
versely, there were no treatment-related effects on the
postinfarction remodeling process, as assessed on the basis
of the similar increase in LV diastolic volumes among the
different experimental groups (Table 1).
Cell Engraftment and Angiogenesis
Clusters of myoblasts were identified by means of histology
as large multinucleated myocytes and mainly by means of
immunohistochemistry as myocytes staining positively for
myosin heavy chain both in the core and in the borders of
the scar. In the group receiving both myoblasts and HIF-1
concomitantly, cell engraftment was associated with a sig-
nificantly greater angiogenesis in the core of the infarct and
along its borders with normal myocardium compared with
that seen in the myoblast-alone group (Figure 2), the num-
ber of capillaries per unit area being 8.5  104 (4.6 
1041.1  103) and 5.3  104 (3.8  1046.5 
104), respectively (P  .023). The extent of cell engraft-
ment into the injected scars was also greater in the com-
bined group than in hearts receiving myoblasts alone, as
reflected by a percentage of myosin-positive areas relative
to the LV infarcted area of 4.49% (0.44%-18.35%) versus
0.95% (0.16%-7.21% [P  .027]). There was no tumor
formation in any heart studied.
Cell Survival
In the subset of experiments in which male myoblasts were
injected into female recipients, the number of grafted cells,
identified by the presence of a Y chromosome by means of
PCR, was also significantly greater after simultaneous coin-
jections of myoblasts and HIF-1 than after cell transplan-
tation alone: 13.16 106 (3.45 10620.89 106) versus
1.56  106 (0.67  1063.42  106 [P  .020, n  4 for
each group]).
Discussion
Main Findings of the Study
The most salient finding of the present study is that the
concomitant intramyocardial administration of HIF-1 and
skeletal myoblasts improved postinfarction LV systolic
function to a greater extent than myoblast grafting alone and
that this improvement correlated with an increase in angio-
genesis, cell survival, and graft area. Conversely, HIF-1
given at the time of infarction failed to provide a similar
The Journal of Thoracibenefit, possibly because of adenoviral inactivation by in-
flammatory and immune processes (cyclosporine might
have not yet been effective at the time of HIF-1 injection
because it had just been started). This hypothesis is indi-
rectly supported by the fact that in the study in which
sequential administration of basic fibroblast growth factor
and fetal cardiomyocytes (injected one week later) was
functionally successful, the factor was incorporated into
controlled-release gelatin hydrogels,21 which might have
provided some protection against environmental inactivat-
ing processes. In contrast, Retuerto and colleagues22 re-
cently reported that intramyocardial injections of an adeno-
virus encoding vascular endothelial growth factor at the
time of infarction enhanced the benefits of fetal cardiomy-
ocyte transplantation performed 3 weeks later. Several dif-
ferences in protocol design, particularly the use of synge-
neic animals in Retuerto’s experiments, might account for
this discrepancy with our data. Furthermore, the lack of
functional benefits in hearts injected with HIF-1 alone is
consistent with the prediction that increasing angiogenesis
in scar tissue that no longer harbors blood flow–dependent
cardiomyocytes is unlikely to affect the contractile patterns
of that fibrous area. This assumption is actually supported
by the observation that the group that yielded the best
functional outcome was the one in which HIF-1 was
delivered concomitantly with living cells (ie, the grafted
myoblasts), the survival of which is expected to benefit from
angiogenesis.
Magnitude and Prevention of Posttransplantation Cell
Death
Up to 90% of cardiomyocytes have been reported to die
over the first 48 hours after their intramyocardial implanta-
tion,14 and a similar attrition rate has been observed with
skeletal myoblasts transplanted in skeletal muscle23 or in
infarcted myocardial areas (unpublished observations from
our laboratory). This major loss of grafted cells is likely to
seriously hamper the functional efficacy of the procedure, as
suggested by the close relationship established in a rat
model of myocardial infarction between the number of
injected myoblasts and the extent of LV preservation.24
A first approach consists of increasing the number of
cells to compensate for the loss of transplanted cells, but this
strategy is plagued with limitations related to practicality
(the duration of cultures should remain within the clinically
acceptable time frame of 2-3 weeks), cost, and safety (the
tolerable volume that can be injected intramyocardially
should probably not exceed 5-6 mL, whereas multiple pas-
sages might favor the emergence of a differentiation-
defective population of cells with a subsequent risk of
inappropriate graft overgrowth).25 An alternate approach
targets the enhancement of cell survival by counteracting
the mechanisms of graft loss.
c and Cardiovascular Surgery ● Volume 130, Number 1 177
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TXThese mechanisms are likely multiple, but apart from
physical strain during injections and the inflammatory reac-
tion triggered by needle punctures, two seem to play a major
role: apoptosis, as demonstrated by the benefits of transfect-
ing mesenchymal stem cells with a prosurvival gene (Akt)
before transplantation26 and ischemia, as demonstrated by
the 2-fold greater increase in cell survival when injections
are made into a richly vascularized tissue, as opposed to a
fibrous scar.14 The results of our myoblasts and HIF-1
group support this concept that enhancing the vascular
supply of the grafted cells optimizes the posttransplantation
functional outcomes by addressing the ischemic component
of cell loss through increased angiogenesis.
As such, our data are consistent with those of previous
studies that have established the benefits of completing cell
transplantation by an additional supply of angiogenic
growth factors. Thus both genetically induced overexpres-
sion of vascular endothelial growth factor by skeletal myo-
blasts27,28 or early differentiated embryonic stem cells29 and
sequential delivery of fibroblast growth factor and fetal
cardiomyocytes21 have been shown to increase angiogene-
sis and improve function compared with results seen in
control animals. However, it is now recognized that admin-
istration of a single angiogenic growth factor has a limited
therapeutic efficacy,30 hence the rationale for the delivery of
a mix of them or, preferably, of a master gene that can
control the expression of a wider array of downstream
effectors. In this setting HIF-1 is attractive because of its
role as a key regulator of gene expression in response to
cellular hypoxia and the multiplicity of its transcriptionally
activated target genes (80) whose protein products play
crucial roles in angiogenesis (particularly through produc-
tion of vascular endothelial growth factor and erythropoie-
tin), cell protection, and metabolic mechanisms (particularly
glucose transport and glycolysis).15 Thus although HIF-1
alone failed to prevent a deterioration of LV function, the
observation that its concomitant delivery with skeletal myo-
blasts further potentiated the cell-mediated benefits (Figure
2) suggests a synergistic action and thus a contribution of
both myogenesis and angiogenesis to the improved func-
tional outcome yielded by the combined therapy group.
Study Limitations
Several limitations of the study need, however, to be ac-
knowledged. First, evidence for the efficacy of HIF-1 is
primarily based on surrogate end points like capillary den-
sity and LV functional indices because we did not measure
directly the expression of HIF-1 in myocardial tissue.
However, the ability of an adenovirus to act as an effica-
cious vector of HIF-1 has been previously demonstrated
by the upregulation of a wide array of HIF-1–dependent
genes in human cardiac cells transfected by these
constructs.20
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delivered by an adenoviral vector in solution coinjected
along with myoblasts. It remains thus possible that a greater
therapeutic efficacy might have been obtained by alternate
modes of gene delivery (direct myoblast transfection and
naked plasmid DNA17) or cotransplantation of cells featur-
ing an angiogenic potential.26,31,32
Third, our PCR data demonstrated an almost 3-fold
greater number of Y chromosome–bearing cells in the com-
bined therapy group than in the myoblast-alone group. This
likely reflects an improved survival of better-vascularized
myoblasts, as suggested by the greater extent of skeletal
myosin-positive areas seen in these hearts receiving myo-
blasts plus HIF-1. Nevertheless, in the absence of a de-
tailed phenotypic characterization, we cannot exclude that
the proliferation of the nonmyogenic cell component of the
initial injectate (ie, fibroblasts and endothelial cells) might
have also contributed to this higher cell count.
Finally, follow-up was limited to 1 month. The relatively
short half-life of adenoviral vectors then raises the question
of the long-term effects of HIF-1 therapy, but the bulk of
cell death occurs shortly after injections14 at a time at which
HIF-1 is still present for triggering an increased angiogen-
esis, which is then expected to persist over time, even if the
trigger has waned.
In conclusion, the present data show that the functional
benefits of skeletal myoblast transplantation can be signif-
icantly enhanced by the concomitant administration of an
adenoviral vector encoding HIF-1, which supports an im-
portant role for ischemia in the genesis of posttransplanta-
tion cell death and suggests that enhancing graft vascular-
ization is an effective means of overcoming this problem.
The potential clinical relevance of these results stems from
the approval of HIF-1 for investigational use in phase I
human trials. More generally, the current findings also il-
lustrate the benefits that can be derived from the synergistic
effects of gene and cell therapy.
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